Results 141 to 150 of about 835,413 (266)

Serum Agalactosyl IgG Predicts Hepatocellular Carcinoma and All‐Cause Mortality After SVR in Advanced Chronic Hepatitis C

Hepatology Research, EarlyView.
ABSTRACT Background and Aims Patients with chronic hepatitis C and advanced fibrosis remain at substantial risk of hepatocellular carcinoma (HCC) and non‐liver–related death even after sustained virological response (SVR) to direct‐acting antivirals (DAA).
Daisuke Sakon, Jumpei Kondo, Yuki Tahata, Hayato Hikita, Maki Iwaisako, Muya Matsumoto, Asuka Ogata, Shinji Takamatsu, Yasutoshi Nozaki, Naruyasu Kakita, Hisashi Ishida, Fumihiko Nakanishi, Yuichi Yoshida, Masanori Nakahara, Kazuho Imanaka, Mitsuru Sakakibara, Takayuki Yakushijin, Tetsuo Takehara, Takahiro Kodama, Eiji Miyoshi   +19 more
wiley   +1 more source

ALPHA-FETOPROTEIN

The Kurume Medical Journal, 1977
openaire   +3 more sources

Alpha-Fetoprotein Is a Potential Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC): A Case Report. [PDF]

Cancer Rep (Hoboken)
Zhong K, Wu X, Lin X, Xie M, Deng M, Tao Q, Qin W, Peng S.   +7 more
europepmc   +1 more source

Alpha-Fetoprotein [PDF]

, 2020
openaire   +1 more source

On‐Treatment Reassessment of Type IV Collagen 7S and M2BPGi‐Qt Improves Long‐Term Hepatocellular Carcinoma Risk Stratification in Chronic Hepatitis B

Hepatology Research, EarlyView.
One‐year reassessment of type IV collagen 7S, supported by quantitative M2BPGi‐Qt assessment, helped refine long‐term hepatocellular carcinoma risk stratification in patients with chronic hepatitis B receiving nucleos(t)ide analogue therapy. On‐treatment 4COL7S emerged as a novel marker of residual fibrosis‐related HCC risk.
Kazumi Yamasaki, Hideko Kozuru, Tomoko Sato, Tomoyuki Suehiro, Yasuhide Motoyoshi, Yuki Kugiyama, Akira Saeki, Shinya Nagaoka, Atsumasa Komori, Hiroshi Yatsuhashi   +9 more
wiley   +1 more source

Refining early detection of hepatocellular carcinoma: The promise of the GALAD score. [PDF]

World J Gastroenterol
Prakash HS, Sehrawat A, Swamy AM, Sundriyal D.   +3 more
europepmc   +1 more source

Rapid Intrasegmental Progression After Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma: Incidence, Imaging Features, and Clinical Outcomes

Hepatology Research, EarlyView.
ABSTRACT Aim Radiofrequency ablation (RFA) is curative therapy for early‐stage hepatocellular carcinoma (HCC), but a rare subset of patients develop aggressive intrasegmental recurrence shortly after complete ablation. We characterized the incidence, risk factors, and absolute risk.
Takuma Kaneko, Takuma Nakatsuka, Ryosuke Tateishi, Keisuke Mabuchi, Yuki Matsushita, Tomoharu Yamada, Tatsuya Minami, Masaya Sato, Mitsuhiro Fujishiro   +8 more
wiley   +1 more source

Development of a longitudinal predictive model for hepatocellular carcinoma occurrence in patients with chronic hepatitis B. [PDF]

Sci Rep
Kaewdech A, Toh C, Sripongpun P, Chamroonkul N, Tangkijvanich P, Piratvisuth T, Liangpunsakul S, Thongsuksai P, Ingviya T.   +8 more
europepmc   +1 more source

Cisterna Chyli Dilation Is a Risk Factor for Liver Nodules and Hepatocellular Carcinoma in Fontan‐Associated Liver Disease: Pathophysiological Role of Lymphatic Dysfunction

Hepatology Research, EarlyView.
ABSTRACT Aim In Fontan‐associated liver disease (FALD), chronic congestion often confounds conventional fibrosis markers, complicating surveillance for hepatocellular carcinoma (HCC). Although lymphatic dysfunction is fundamental to Fontan physiology, its contribution to hepatocarcinogenesis remains unclear.
Koji Imoto, Masatake Tanaka, Takeshi Goya, Yuuki Azuma, Tomonobu Hioki, Yusuke Morita, Keisuke Sakaguchi, Nobuhiro Fujita, Takamori Kakino, Ayako Ishikita, Kenichiro Yamamura, Ichiro Sakamoto, Kousei Ishigami, Kohtaro Abe, Yoshihiro Ogawa   +14 more
wiley   +1 more source

Durable response to FOLFOX plus serplulimab in AFP-producing gastric adenocarcinoma with liver metastases: a case report and literature review. [PDF]

Front Immunol
Jin Y, Fu L, Zhao Y, Tong Z, Tan Y.
europepmc   +1 more source